Inducement Grants Signal Replimune’s Commitment to Talent Growth Replimune has awarded equity inducements to 53 new non-executive hires, totaling over 98,000 stock options and 155,000 restricted stock units. This move, under Nasdaq’s inducement rule, aims to attract and retain skilled personnel as the biotech advances late-stage immunotherapy programs and prepares for possible commercial expansion in melanoma treatment.45